Evidence map›Paper›PMID 36321854›Full record

ReviewChemical communications (Cambridge, England)2022

Sugyeom Kim, Jeremy Oiler, Yalan Xing, George A O'Doherty

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chemical communications (Cambridge, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sugyeom KimDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA, 02115, USA. G.ODoherty@neu.edu.ORCID http://orcid.org/0000-0001-8128-8648
Jeremy OilerDepartment of Chemistry, William Paterson University, Wayne, NJ, 07470, USA.
Yalan XingDepartment of Chemistry, Hofstra University, Hempstead, NY, 11549, USA. Yalan.Xing@hofstra.edu.ORCID http://orcid.org/0000-0003-1176-9969
George A O'DohertyDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA, 02115, USA. G.ODoherty@neu.edu.ORCID http://orcid.org/0000-0002-1699-2249

Funding

De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize SelectivityR01AI154860 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2020 to 2023
$3.1M
Apramycin scaffold exploration using novel glycochemistry and SAR studies to enhance activity against Acinetobacter baumannii and other multidrug-resistant Gram-negative pathogensR21AI142040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$476k
Fusidic acid derivatization to enhance entry into Gram-negative pathogensR21AI146485 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$475k
NIAID NIH HHS R01 AI154860NIAID NIH HHS R21 AI142040NIAID NIH HHS R21 AI146485
6 · The paper itself

Abstract

The development and application of the asymmetric synthesis of oligosaccharides from achiral starting materials is reviewed. This

Indexed as

Biological ProductsCatalysisGlycosylationOligosaccharidesPalladiumStereoisomerismBiological ProductsOligosaccharidesPalladium

Identifiers

PMID36321854
PMCPMC9710213

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.